Veracyte, Inc.
Veracyte, Inc. (VCYT) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
vcyt · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Veracyte, Inc. (VCYT) measures how much investors pay for each dollar of the company's trailing earnings. VCYT's current PE ratio of 42.72x is calculated by dividing its stock price of $47.27 by its TTM earnings per share of $1.11. −51.3% discount vs 5Y avg 87.7x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Veracyte, Inc.You VCYT | $3.8B | 42.72x | -55.8% | $1.11 |
 Adaptive Biotechnologies Corporation ADPT | $2.7B | N/A | — | -$0.39 |
 Apellis Pharmaceuticals, Inc. APLS | $5.3B | 141.40x | +46.3% | $0.18 |
 Amicus Therapeutics, Inc. FOLD | $4.5B | N/A | — | -$0.09 |
 IDEAYA Biosciences, Inc. IDYA | $2.8B | N/A | — | -$1.28 |
 Disc Medicine, Inc. IRON | $2.5B | N/A | — | -$6.01 |
 Kiniksa Pharmaceuticals, Ltd. KNSA | $3.7B | 51.87x | -46.3% | $0.80 |
Industry Average 2 peers with valid PE | — | 96.64x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 49.86x | $0.84 | -60.3% | |
2024-12-31 FY2024 | 125.48x | $0.32 | — | |
2023-12-31 FY2023 | — | $-1.02 | — | |
2022-12-31 FY2022 | — | $-0.51 | — | |
2021-12-31 FY2021 | — | $-1.11 | — | |
2020-12-31 FY2020 | — | $-0.66 | — | |
2019-12-31 FY2019 | — | $-0.27 | — | |
2018-12-31 FY2018 | — | $-0.62 | — | |
2017-12-31 FY2017 | — | $-0.91 | — | |
2016-12-31 FY2016 | — | $-1.09 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Veracyte, Inc. (VCYT) measures how much investors pay for each dollar of the company's trailing earnings. VCYT's current PE ratio of 42.72x is calculated by dividing its stock price of $47.27 by its TTM earnings per share of $1.11.
Frequently asked questions
VCYT pe ratio · 6 questionsVCYT's current PE ratio is 42.72x as of 2026-06-08, based on a stock price of $47.27 and TTM EPS of $1.11. Data sourced from Financial Modeling Prep via VCYT's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Veracyte, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08